Shots: Oncoheroes to get IP rights with an exclusive right to research, develop, sell and sublicense Boehringer’s Volasertib. Oncoheroes will further develop & commercialize volasertib for pediatric cancer indications The […]readmore
Tags : Boehringer Ingelheim
1.Roche’s Tecentriq + Chemotherapy Receives EC’s Approval as 1L Treatment for Extensive Stage Small Cell Lung Cancer Published: Sept 06, 2019 | Tags: Roche, Tecentriq, Chemotherapy, Receives, EC, Approval, Initial Treatment, […]readmore
Shots: Lupin to receive $20M up front, ~$700M as clinical, regulatory & commercial milestones with royalties on sales of the product. Boehringer Ingelheim to get right to utilize Lupin’s LNP3794 […]readmore
Shots: The advancement of BI 456906 to P-II study is based on the safety and tolerability and a wt. loss in individuals with a BMI up to 40 kg/m2 , […]readmore
Profound Medical’s TULSA-PRO Receives the US FDA’s 510(k) Clearance for Ablation of Prostate Tissue Published: Aug 16, 2019 | Tags: 510(k), Ablation, Clearance, Profound Medical, Prostate Tissue, Receives, TULSA-PRO, The US […]readmore
Shots: The companies collaborated to establish a Virtual Research and Development Center, enabling data sharing and analysis and focusing on research of therapies for multiple types of cancers, including gastrointestinal […]readmore
Shots: The INMARK study involves assessing of Ofev (nintedanib) vs PBO in 347 patients with IPF for 12 wks., followed by an open label period of 40 wks. The study […]readmore
Shots: Bridge to receive $50.66M as up front and near-term payments, up to $1.23B based on development, regulatory, and commercial milestones and royalties on sales The focus of the collaboration […]readmore
Shots: Boehringer Ingelheim acquires AMAL Therapeutics in all-stock transaction for ~$478.5M. AMAL to get $365.9M including up front, clinical, development, regulatory milestones and $112.6M as commercial milestones The focus of […]readmore
Shots: The P-IIb/III DIVERSITY study involve assessing of Pradaxa vs SOC (heparin or vitamin K antagonist) in children with acute VTE requiring anticoagulation therapy for 3mos. aged ≤18yrs. resulted in […]readmore